PGPeilan Guo

Peilan Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peilan Guo has a total of 29 co-authors. Here are the top co-authors by number of shared publications:

  • Slawomir Wolczynski

    Department of Reproduction and Gynecological Endocrinology Medical University of Bialystok Bialystok 37801 Poland

    2 shared publications
  • Agata Pilaszewicz-Puza

    Department of Pathomorphology, Medical University of Bialystok, Bialystok, Poland

    1 shared publication
  • Donata Ponikwicka-Tyszko

    Department of Biology and Pathology of Human Reproduction, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, Olsztyn, Poland

    1 shared publication
  • Fujun Liu

    Yantai Yuhuangding Hospital Affiliated to Qingdao University Shandong 264000 China

    1 shared publication
  • Herjan J.T. Coelingh Bennink

    Pandora Endocrine Innovation, Werkhoven, the Netherlands

    1 shared publication
  • Ilpo Huhtaniemi

    Institute of Biomedicine, University of Turku, Turku, Finland; Institute of Reproductive and Developmental Biology, Imperial College London, London, United Kingdom

    1 shared publication

Latest Publications

  • Open Access

    CircSMEK1 Suppresses HCC via the hnRNPK‐IGF2‐AKT Axis: A Diagnostic Biomarker and Therapeutic Target

    by Peilan Guo, Xiaomeng Jia, Shenghong Wang, Xinyu Li, Yajing Liu, Lisen Lin, Zhengkun Wang, Fujun Liu, Slawomir Wolczynski, Nafis Rahman, et al.

    The mechanism underlying metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC) is elusive, and whether circRNA can serve as biomarker or therapeutic target for MASH/HCC needs to be systematically explored. Integrative transcriptomic analysis of circRNA from MASH and HCC were performed. Multi‐cohort analyses of serum and tissues from MASH and HCC patients ( n = 206) were conducted. Mechanisms are explored via RNA‐protein interaction assays, CRISPR‐mediated knockdown, and xenograft/PiggyBac‐mediated mice models. circSMEK1 is significantly decreased in MASH/HCC tissues and serum, correlating with tumor size, vascular invasion, and overall survival. Mechanistically, nuclear circSMEK1 binds hnRNPK, promoting its ubiquitin‐mediated degradation, suppressing IGF2 transcription and PI3K/AKT signaling. Loss of circSMEK1 elevated autocrine IGF2 in HCC promoting tumor growth, also activated AKT in cancer‐associated fibroblasts through paracrine, fostering an immunosuppressive microenvironment. SF3B4 overexpression drove circSMEK1 depletion in HCC. In murine models, circSMEK1 restoration inhibited tumor growth and metastasis. circSMEK1 is a tumor‐suppressor in MASH/HCC through the hnRNPK‐IGF2‐AKT axis. The serum level of circSMEK1 has non‐invasive diagnostic value for HCC (AUC = 0.790), as well as potential diagnostic utility for early HCC or high‐risk MASH, owing to its key role in bridging MASH to HCC progression. Restoring of circSMEK1, alone or combined with IGF2 inhibitors, proposing a novel therapeutic strategy for HCC.


  • Open Access

    Novel expression of zona pellucida 3 protein in normal testis; potential functional implications

    by Kamila Pulawska, Donata Ponikwicka-Tyszko, Weronika Lebiedzinska, Peilan Guo, Piotr Bernaczyk, Agata Pilaszewicz-Puza, Xiangdong Li, Marcin Chrusciel, Oana Lupu, Sini Leskinen, et al.